| Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency JCN Chan, R Scott, JC Arjona Ferreira, D Sheng, E Gonzalez, MJ Davies, ... Diabetes, Obesity and Metabolism 10 (7), 545-555, 2008 | 381 | 2008 |
| Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non … S Portsmouth, D van Veenhuyzen, R Echols, M Machida, JCA Ferreira, ... The Lancet Infectious Diseases 18 (12), 1319-1328, 2018 | 373 | 2018 |
| Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency JC Arjona Ferreira, M Marre, N Barzilai, H Guo, GT Golm, CMC Sisk, ... Diabetes care 36 (5), 1067-1073, 2013 | 205 | 2013 |
| Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa B Cai, R Echols, G Magee, JC Arjona Ferreira, G Morgan, M Ariyasu, ... Open forum infectious diseases 4 (3), ofx176, 2017 | 170 | 2017 |
| Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial JCA Ferreira, D Corry, CE Mogensen, L Sloan, L Xu, GT Golm, ... American Journal of Kidney Diseases 61 (4), 579-587, 2013 | 154 | 2013 |
| Treatment of uterine fibroid symptoms with relugolix combination therapy A Al-Hendy, AS Lukes, AN Poindexter III, R Venturella, C Villarroel, ... New England Journal of Medicine 384 (7), 630-642, 2021 | 147 | 2021 |
| Development of aprepitant, the first neurokinin‐1 receptor antagonist for the prevention of chemotherapy‐induced nausea and vomiting R Hargreaves, JCA Ferreira, D Hughes, J Brands, J Hale, B Mattson, ... Annals of the New York Academy of Sciences 1222 (1), 40-48, 2011 | 142 | 2011 |
| Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials M Hale, J Wild, J Reddy, T Yamada, JCA Ferreira The lancet Gastroenterology & hepatology 2 (8), 555-564, 2017 | 136 | 2017 |
| Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double‐blind trial Y Iwamoto, N Tajima, T Kadowaki, K Nonaka, T Taniguchi, M Nishii, ... Diabetes, Obesity and Metabolism 12 (7), 613-622, 2010 | 130 | 2010 |
| Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus Y Iwamoto, T Taniguchi, K Nonaka, T Okamoto, K Okuyama, JCA Ferreira, ... Endocrine journal 57 (5), 383-394, 2010 | 115 | 2010 |
| Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study LR Webster, S Nalamachu, B Morlion, J Reddy, Y Baba, T Yamada, ... Pain 159 (5), 987-994, 2018 | 89 | 2018 |
| Cefiderocol, a siderophore cephalosporin for gram‐negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment T Katsube, R Echols, JC Arjona Ferreira, HK Krenz, JK Berg, C Galloway The Journal of Clinical Pharmacology 57 (5), 584-591, 2017 | 87 | 2017 |
| Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function T Katsube, T Wajima, T Ishibashi, JC Arjona Ferreira, R Echols Antimicrobial Agents and Chemotherapy 61 (1), 10.1128/aac. 01381-16, 2017 | 84 | 2017 |
| Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 … LC Giudice, S As-Sanie, JCA Ferreira, CM Becker, MS Abrao, BA Lessey, ... The Lancet 399 (10343), 2267-2279, 2022 | 77 | 2022 |
| A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients … LR Webster, T Yamada, JC Arjona Ferreira Pain Medicine 18 (12), 2350-2360, 2017 | 76 | 2017 |
| Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 … AS Dobs, BJ Goldstein, P Aschner, ES Horton, GE Umpierrez, L Duran, ... Journal of diabetes 5 (1), 68-79, 2013 | 52 | 2013 |
| Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control N Tajima, T Kadowaki, M Odawara, M Nishii, T Taniguchi, ... Diabetology international 2, 32-44, 2011 | 39 | 2011 |
| Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in J apanese patients with type 2 diabetes over 52 weeks T Kadowaki, N Tajima, M Odawara, M Nishii, T Taniguchi, JCA Ferreira Journal of Diabetes Investigation 4 (2), 174-181, 2013 | 30 | 2013 |
| Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy T Kadowaki, N Tajima, M Odawara, T Minamide, M Kawashima, ... Diabetology International 4, 160-172, 2013 | 27 | 2013 |
| Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes A Kashiwagi, T Kadowaki, N Tajima, K Nonaka, T Taniguchi, M Nishii, ... Journal of Diabetes Investigation 2 (5), 381-390, 2011 | 27 | 2011 |
